Survivors Share Their Stories

From in Good Health CNY, October 2024

 

Lilie Welych

A ‘thriver’ describes her cancer journey

By Mary Beth Roach

Lilie Welych considers herself a “thriver.”

And she proudly wears an alphabet-bead bracelet that spells out TNBC THRIVER.

TNBC stands for triple negative breast cancer, which she was diagnosed with two years ago.

Today, that thriver is in remission and NED (no evidence of disease).

Esophageal, MK3475-06C-U02 “KEYMAKER-U02”

A Phase 1/2 Open-Label, Umbrella Platform Design Study of MK-2870 With Pembrolizumab (MK-3475) and Chemotherapy in Participants with 1L Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, and Esophageal. Substudy 06C

Esophageal, MK3475-06B-05 “KEYMAKER-U02”

A Phase 1/2 Open-Label, Umbrella Platform Design Study of Investigational Agents With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants with Advanced Esophageal Cancer Previously Exposed to PD-1/PD-L1 Treatment (KEYMAKER-U06): Substudy 06B.

Mantel Cell, A052101

This phase III trial tests whether continuous or intermittent zanubrutinib after achieving a complete remission (CR) with rituximab works in older adult patients with mantle cell lymphoma (MCL) who have not received treatment in the past (previously untreated.) 

Multiple Myeloma, A151804

This trial collects research data and samples from patients who experience immunotherapy side effects to store for use in future research studies. Studying research data and samples from patients who experience immunotherapy side effects may help researchers better understand how to predict, prevent, and treat these side effects.

Solid Tumor, ART0380C001 “ARTIOS”

A Phase I/IIa, Open-label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients with Advanced or Metastatic Solid Tumors.

Pancreas, Tempus Aries TP-CA-007

A Second Line Biobank Registry Platform Study in Oncology Patients with KRAS mutated CRC, NSCLC & PDAC. Reference arm study to evaluate ctDNA kinetics and dynamics in response to standard of care therapy in patients with relapsed and metastatic KRAS-mutated NSCLC to enable novel biomarker discovery and drug development.

Colorectal, Tempus Aries TP-CA-007

A Second Line Biobank Registry Platform Study in Oncology Patients with KRAS mutated CRC, NSCLC & PDAC. Reference arm study to evaluate ctDNA kinetics and dynamics in response to standard of care therapy in patients with relapsed and metastatic KRAS-mutated NSCLC to enable novel biomarker discovery and drug development.

Lung, Tempus Gemini TP-CA-002

GEMINI NSCLC Study is a non-interventional study that will be collecting clinical and molecular health information from patients with NSCLC who will receive longitudinal blood collection in addition to their standard of care therapy and disease surveillance with the goals of identifying the molecular evolution of lung cancer with standard of care therapy, and determining the utility of ctDNA dynamics to predict risk of recurrence and therapeutic outcomes.

Lung, Tempus Aries TP-CA-007

A Second Line Biobank Registry Platform Study in Oncology Patients with KRAS mutated CRC, NSCLC & PDAC. Reference arm study to evaluate ctDNA kinetics and dynamics in response to standard of care therapy in patients with relapsed and metastatic KRAS-mutated NSCLC to enable novel biomarker discovery and drug development.

Pages